SCHEDULE: Trails Edge Capital Boosts Milestone Pharma Stake to 9.9%

Trails Edge Capital Partners, LP, along with its affiliates, has disclosed a 9.9% beneficial ownership stake in Milestone Pharmaceuticals Inc., primarily through common shares and exercisable warrants.

Summary

• Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai collectively reported beneficial ownership of 9,017,880 common shares of Milestone Pharmaceuticals Inc.
• This represents 9.9% of the outstanding common shares of Milestone Pharmaceuticals Inc. as of September 30, 2025.
• The ownership includes 3,833,333 shares held directly by Trails Edge Biotechnology and 5,184,547 shares underlying Series A warrants.
• The reporting persons have sole voting and dispositive power over all 9,017,880 shares.
• The reported ownership percentage is based on 84,994,261 shares outstanding as of August 12, 2025, as per Milestone Pharmaceuticals Inc.'s Form 10-Q.
• Warrants for an additional 148,786 Series A shares and 5,333,333 Series B shares are excluded from the beneficial ownership calculation due to a 9.99% ownership limitation clause.

Sentiment

Score: 7

Explanation: The disclosure of a 9.9% beneficial ownership by a specialized investment firm like Trails Edge Capital Partners is generally viewed as a positive indicator of investor confidence in Milestone Pharmaceuticals Inc. The substantial stake suggests a belief in the company's long-term value or strategic direction.

Positives

• A significant institutional investor, Trails Edge Capital Partners, LP, has taken or maintained a substantial 9.9% stake in Milestone Pharmaceuticals Inc., indicating confidence in the company's prospects.
• The investment includes both direct shareholdings and exercisable warrants, providing potential for future increased ownership.

Negatives

• The filing itself does not present any negative information regarding Milestone Pharmaceuticals Inc.'s operations or financial health.

Future Outlook

The filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from Milestone Pharmaceuticals Inc. or the reporting persons regarding the issuer's future performance.

Management Comments

• The filing does not contain direct quotes or paraphrased statements from Milestone Pharmaceuticals Inc.'s management. It includes certifications from Ortav Yehudai on behalf of the reporting entities.

Industry Context

The disclosure of a significant stake by an investment manager specializing in biotechnology, such as Trails Edge Capital, can signal investor interest in the pharmaceutical or biotechnology sector, particularly for companies like Milestone Pharmaceuticals Inc. This type of investment activity is common in the biotech industry where specialized funds seek to capitalize on potential drug development or market opportunities.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a near-10% stake could be seen positively, potentially increasing confidence and attracting further investment.
• Company Management: Awareness of a large, active shareholder may influence strategic decisions or engagement.

Key Dates

Recommendation

The filing indicates a significant beneficial ownership by Trails Edge Capital Partners, LP and its affiliates in Milestone Pharmaceuticals Inc., representing 9.9% of the outstanding shares. This substantial stake, including both direct shares and exercisable warrants, suggests a strong conviction from a specialized institutional investor. While this is generally a positive signal, the Schedule 13G filing itself does not provide sufficient operational or financial performance data to issue a 'buy' or 'sell' recommendation. Investors should 'hold' and monitor further company developments and financial reports to make a more informed decision, considering this significant institutional backing as a positive factor.

Keywords

Milestone Pharmaceuticals Inc., Trails Edge Capital Partners, Trails Edge Biotechnology Master Fund, Ortav Yehudai, Schedule 13G, Beneficial Ownership, Common Shares, Warrants, Institutional Investor, Biotechnology, Pharmaceuticals